In short
Clinical trials are investigating Hydralazine Hydrochloride in people with chronic heart failure and reduced left ventricular ejection fraction. These studies look at whether treatment can lower serious heart failure events, hospitalizations, and urgent treatment needs. The main focus is on patients already on optimal heart failure therapy.
Key points
- Clinical trials investigating Hydralazine Hydrochloride in the source data focus on people with chronic heart failure and reduced left ventricular ejection fraction. The main study is a Phase 3 trial called DANHEART, which enrolled 1,500 participants. It looked at whether Hydralazine Hydrochloride, given as part of Hydralazine/isosorbide dinitrate, could reduce death, hospitalizations, urgent treatment visits, and other serious heart failure events. The same trial also studied metformin in a separate comparison. Overall, the trials are centered on major heart failure outcomes in patients already on optimal treatment.
Trial overview
The main trial in the source data was DANHEART, a completed Phase 3 study in people with heart failure. It studied Hydralazine Hydrochloride as part of a Hydralazine/isosorbide dinitrate treatment group and also included a separate metformin comparison.
Who was studied
The trial focused on patients with chronic heart failure and reduced left ventricular ejection fraction of 40% or less. The brief summary says these patients were already on optimal treatment, which means they were receiving the best standard care used in the study setting.
What the trial measured
The main outcome for the Hydralazine/isosorbide dinitrate part of the trial was a combined measure of serious heart failure events. These events included death, hospitalization with worsening heart failure, urgent visits that needed intravenous therapy or metolazone therapy, heart transplantation, or implantation of a left ventricular assist device (LVAD).
The metformin part of the study used a broader combined outcome that also included acute myocardial infarction and stroke. A composite endpoint means the study counts several important outcomes together instead of looking at only one event.
Trial phase and size
DANHEART was a large Phase 3 trial with an enrollment of 1,500 people. Phase 3 studies are usually done to see whether a treatment helps a meaningful number of patients and to collect more information in a larger group.
Treatments in the study
The intervention list included BiDil, placebo for Hydralazine/isosorbide dinitrate, placebo for metformin hydrochloride, and metformin hydrochloride. In the source data, Hydralazine Hydrochloride appears in the Hydralazine/isosorbide dinitrate treatment group rather than as a stand-alone study drug.
- BiDil was given orally in the study.
- Placebo means an inactive look-alike treatment used for comparison.
- Metformin hydrochloride was also studied in the same trial, showing that DANHEART compared more than one approach.
What this means for patients
Based on the source data, the research on Hydralazine Hydrochloride is centered on serious outcomes in heart failure, not on short-term symptoms alone. The trial population was specific: adults with chronic heart failure, reduced pumping function of the heart, and ongoing standard treatment. Because the study is completed, the data are meant to help researchers understand whether the treatment strategy lowered major heart failure events in this group.